# Effects of Denosumab on the Pharmacokinetics of Etanercept

> **NCT01294397** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 19 (actual)

## Conditions studied

- Postmenopausal
- Osteopenia
- Rheumatoid Arthritis
- Osteoporosis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT01294397
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Lack of enrollment.
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294397, "Effects of Denosumab on the Pharmacokinetics of Etanercept". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01294397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*